解决了传统柔性电极在大脑中易移位、易脱出的核心痛点。 作者丨杨婧雪 编辑丨刘恒涛 2月11日，侵入式柔性电极脑机接口公司智冉医疗宣布完成A+轮融资，本轮融资金额达3亿元，由中 科创星领投，老股东君联资本、北京市医药健康产业投资基金、IDG资本、顺为资本、联想创投、元 生创投、红杉中国、美团龙珠、BV百度风投、杏泽资本、佳银资本持续跟投。据悉，本轮融资将主要 用于推进大规模临床试验与高通量柔性脑机接口产品迭代，加速该技术向临床应用落地。 | | | 北京智冉医疗科技有限公司--融资历程 | | | | --- | --- | --- | --- | --- | | 融资轮次 | 事件时间 | 融资金额 | 估值/市值 | 投资方 | | | | | | 中科创星领投 BV百度风投 | | | | | | IDG资本 | | | | | | 佳银基金 | | | | | | 顺禧基金 | | A+轮 | 2026年2月11日 | 3亿人民币 | 未披露 | 君联资本 Legend Capital | | | | | | 元生创投 | | | | | | 美团龙珠 | | | | | | 联想创投 | | | | ...

Core Viewpoint - Beijing Zhirun Medical Technology Co., Ltd. has completed over 300 million RMB in Series A financing, indicating strong market recognition of its technology and commercialization prospects [3] Group 1: Company Overview - Zhirun Medical focuses on developing a next-generation invasive flexible brain-computer interface (BCI) platform, aiming to revolutionize human-machine interaction [4][5] - Since its establishment in 2022, Zhirun Medical has raised nearly 500 million RMB in total funding, reflecting significant investor confidence in its technological direction [3] Group 2: Technology and Innovation - The invasive BCI technology is gaining attention due to its high bandwidth capabilities, which surpass non-invasive and semi-invasive methods in signal acquisition and neural control [5] - Zhirun Medical has chosen the challenging invasive technology route, similar to Elon Musk's Neuralink, based on a deep understanding of BCI technology's essence [5][6] Group 3: Key Technical Developments - The core of invasive BCI development lies in electrode technology, with Zhirun Medical pioneering high-throughput flexible electrodes that have received patent authorization in both China and the U.S. [7] - The company's innovative design addresses electrode displacement issues, significantly reducing inflammation and ensuring long-term signal stability [7][10] Group 4: Strategic Positioning and Future Plans - Zhirun Medical has established a complete closed-loop system from R&D to large-scale production, ensuring full control over clinical-grade products [10] - The company is well-positioned to leverage recent government policies aimed at promoting BCI industry innovation, aligning its strategy with national objectives [10][11] Group 5: Market Potential and Investor Sentiment - Investors express strong confidence in the commercial potential of invasive BCI technology, highlighting Zhirun Medical's unique position in the market and its comprehensive approach to technology development [11][12] - The company is seen as a leading contender in the BCI field, with expectations for its technology to address unmet medical needs and expand into various applications [11][12][12]